| mycophenolate sodium / Generic mfg. |
| Not yet recruiting | 4 | 28 | | | Heath Department of Western Australia, Novartis Pharmaceutical Company Pty Ltd, Novartis Pharmaceutical Company Pty Ltd | Cardiovascular risk | | | | |
MyERA, ChiCTR-OPC-15006244: Multicenter, prospective study of the effectiveness under immunosuppressive regimens using Myfortic to treat renal transplant recipients from Donation after Circulatory Death in China |
|
|
| Not yet recruiting | 4 | 500 | | Nil | First affiliated hospital, College of Medicine, Zhejiang university; Level of the institution：, sponsored by Novartis | Renal transplantation | | | | |
2005-004607-11: Prospective, randomized, long-term study compairing a Neoral (C-0h monitoring)-based steroid-free to an everolimus-myfortic based, calcineurin-inhibitor-free immunosuppressive treatment on graft function and on the long term impact on cardiovascular risk factors after "de novo" kidney transplantation. |
|
|
| Ongoing | 4 | 120 | Europe | Myfortic, certican, sodium mycophenolate, Neoral, Capsule*, Myfortic 180 mg, Certican 0.25 mg, Myfortic 360 mg, Certican 0.50 mg, Certican 0.75 mg, Neoral 10 mg, Neoral 25 mg, Neoral 50 mg, Neoral 100 mg | Hopital Erasme | “De novo†renal transplantation | | | | |
2013-004934-14: EVEROLIMUS VERSUS MYCOPHENOLIC ACID IN SIMULTANEOUS PANCREAS AND KIDNEY TRANSPLANTATION TO EVALUATE THE DIFFERENCES IN RETINAL NEOVASCULARIZATION IN PATIENTS WITH DIABETIC RETINOPATHY EVEROLIMUS VERSUS MYKOFENOLOVà KYSELINA U PACIENTÅ® PO KOMBINOVANÉ TRANSPLANTACI LEDVINY A SLINIVKY BŘIÅ Nà ZA ÚČELEM ZHODNOCENà VÃVOJE NOVOTVORBY CÉV NA SÃTNICI U PACIENTÅ® S DIABETICKOU RETINOPATIà |
|
|
| Ongoing | 4 | 60 | Europe | Certican, Myfortic, Tablet, Certican, Myfortic | Institut klinické a experimentálnà medicÃny, Institut klinické a experimentálnà medicÃny | simultaneous pancreas/kidney allograft transplantation simultánnà transplantace pankreatu a ledviny, simultaneous pancreas/kidney allograft transplantation simultánnà transplantace pankreatu a ledviny, Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Surgical Procedures, Operative [E04] | | | | |
2005-001830-34: The use of Myfortic in paediatric patients after liver transplantation |
|
|
| Ongoing | 4 | 10 | Europe | Myfortic, ERL080, Myfortic, Myfortic | King\'s College Hospital | Liver transplantation | | | | |
2006-004709-24: Mycophenolate sodium (Myfortic®) in the Treatment of Uveitis: a Pilot Study. |
|
|
| Ongoing | 4 | 24 | Europe | Myfortic, Neoral, Prednison, Neoral, Neoral | ErasmusMC | Uveitis | | | | |
2007-002201-53: An observational study of i)mini-area-under-the-curve (mini-AUC) estimation of exposure to mycophenolic acid (MPA) in heart transplant and lung transplant recipients on mycophenolate mofetil (MMF)or Mycophenolate Sodium (Myfortic) ii) utility of salivary measurements of MPA levels in heart & lung transplant recipients. |
|
|
| Ongoing | 4 | 50 | Europe | Myfortic, Cellcept, Myfortic, Cellcept, Myfortic, Cellcept | University Hospital of South Manchester Nhs Foundation Trust | Immunosuppression after heart and lung transplantation | | | | |
2006-004773-99: A RANDOMISED CONTROLLED TRIAL COMPARING THE USE OF SIROLIMUS BASED BIPHASIC IMMUNOSUPRESSION WITH MYFORTIC TO ALLOW EARLY CNI WITHDRAWAL IN RENAL TRNASPLANTATION |
|
|
| Ongoing | 4 | 42 | Europe | Rapamune, Rapamune, Prograf, Myfortic, Rapamune, Prograf, Myfortic | University Hospitals Leicester | Chronic Allograft Nephropathy | | | | |
2007-003649-34: RENAL RESCUE IMMUNOSUPPRESSION FOLLOWING HEART TRANSPLANTATION |
|
|
| Ongoing | 4 | 56 | Europe | Mycophenolic acid, Ciclosporin, Tacrolimus, Azathioprine, Mycophenolate mofetil, Myfortic, Neoral, Prograf, Cellcept, Myfortic, Neoral, Prograf, Cellcept | University Hospital of South Manchester NHS Foundation Trust | Renal impairment following heart transplantation | | | | |
2013-000766-11: Etude pilote, prospective, multicentrique, randomisée, en ouvert, comparant deux protocoles d’immunosuppression utilisant en traitement d’induction : soit un anticorps monoclonal antirécepteur de l’Interleukine 2 (Simulect®), soit des globulines antilymphocytaires (ATG® Frésénius), associés à une trithérapie Prograf®, Myfortic® et corticoïdes, pour la prévention du rejet chez les adultes transplantés rénaux immunisés de novo. |
|
|
| Ongoing | 4 | 60 | Europe | ATG® frésénius, Simulect® (Basiliximab), ATG® frésénius, Simulect® (Basiliximab) | CHU Toulouse, FRESENIUS, NOVARTIS | Prévention du rejet chez les adultes transplantés rénaux | | | | |
ChiCTR-IPR-16009202: The prevalence of BK virus infection in De Novo Kidney Transplant Recipients Receiving Mizoribine or Mycophenolic Acid: A Prospective, Randomized, Multicenter Study in China |
|
|
| Recruiting | 4 | 200 | | MZR ;MMF/EC-MPS | Beijing Friendship Hospital, Capital Medical University; Beijing Friendship hospital, Capital Medical University, self-raised | Kidney transplantation | | | | |
2021-003089-11: Treatment of Early Borderline Lesions in Low Immunological Risk Kidney Transplant Patients (TRAINING) Tratamiento de las lesiones inflamatorias borderline precoces en pacientes con trasplante renal de bajo riesgo inmunológico (TRAINING) |
|
|
| Not yet recruiting | 4 | 80 | Europe | Grafalon, Advagraf, Envarsus, Cellcept, Myfortic, Prednisona, Tacrolimus, Concentrate for solution for infusion, Capsule, Grafalon. Anti-T Lymphocyte Immunoglobulin For Human Use, Rabbit. Intravenous Use. Neovii Biotech Gmbh, Advagraf, Envarsus, Cellcept, Myfortic, Prednisona | Fundación Canaria Instituto de Investigación Sanitaria de Canarias (FIISC), Fundación Canaria Instituto de Investigación Sanitaria de Canarias (FIISC), Instituto de Salud Carlos III | Subclinical inflammation, including borderline lesions (BL), is very common after kidney transplantation (KT), even in low immunological risk patients, and can lead to interstitial fibrosis/tubular atrophy (IFTA) and worsening of renal function with graft loss. The aim of the study is to determine whether the treatment of early BL (3rd month post-KT) with Grafalon decreases the progression of IFTA and the worsening of graft function compared to conventional therapy after two years post-KT. La inflamación subclínica, es muy frecuente tras el trasplante renal (TX), aún en los pacientes de bajo riesgo inmunológico, y puede evolucionar a lesiones crónicas tipo fibrosis intersticial/ atrofia tubular (FIAT) y deterioro de la función renal. El objetivo es determinar si el tratamiento precoz de las lesiones borderline (3 m post-TX) con Grafalon disminuye la progresión de FIAT y deterioro de la función renal comparado con la terapia convencional después de dos años de seguimiento post-TX., The aim of the clinical trial is to study whether treatment of subclinical graft inflammation with grafalon improves kidney function and graft survival. El objetivo del ensayo clínico es estudiar si el tratamiento de la inflamación subclínica del injerto con grafalon mejora la función renal y la supervivencia del injerto., Not possible to specify | | | | |
2022-000617-13: prospective, randomized, controlled study evaluating the effect of conversion from tacrolimus treatment to mTor inhibitor-based immunosuppression + tacrolimus to boost conversion to positive SARS-CoV-2 serology after a fourth dose of the vaccine of SARS-CoV-2 mRNA in solid organ transplant recipients who have not previously responded. Un estudio prospectivo, aleatorizado y controlado que evalúa el efecto de la conversión del tratamiento de tacrolimus a la inmunosupresión basada en inhibidores de mTor + tacrolimus para reforzar laconversión a positivo e la serología del SARS-CoV-2 después de una cuarta dosis de la vacuna de ARNm del SARS-CoV-2 en pacientes receptores de trasplante de órgano sólido que no han respondido previamente. |
|
|
| Ongoing | 4 | 50 | Europe | Oral solution, Tablet, Capsule, hard, Rapamune, Myfortic, Cellcept | Fundació Hospital Universitari Vall d'Hebron - Institut de Recerca (VHIR), Fundació Hospital Universitari Vall d'Hebron - Institut de Recerca (VHIR) | Seroconversion is evaluated after changing treatment from tacrolimus to tacrolimus + mTOR inhibitor in solid organ transplant patients who have not responded to the first three doses of the vaccine Se evalua la seroconversión tras el cambio de tratamiento de tacrolimus a tacrolimus + inhibidor de mTOR de los pacientes trasplantados de órgano sólido que no hayan respondido a las tres primeras dosis de la vacuna, Se evalúa si los pacientes crean anticuerpos contra la covid tras cambiar el tratamiento a tacrolimus + imTOR en pacientes trasplantados que no han respondido a las tres primeras dosis de la vacuna It's evaluated if patients create antibodies against covid after changing treatment to tacrolimus + imTOR in transplant patients who have not responded to the first three doses of the vaccine, Body processes [G] - Immune system processes [G12] | | | | |
NCT02081755: Safety and Efficacy of Everolimus Treatment in Liver Transplantation for Liver Cancer |
|
|
| Active, not recruiting | 4 | 336 | US | Everolimus, Zortress, Afinitor, Tacrolimus, Prograf, Myfortic, Mycophenolic Acid, CellCept, Mycophenolate Mofetil, Imuran, Azathioprine | Baylor Research Institute | Carcinoma, Hepatocellular | 06/24 | 06/24 | | |
| Recruiting | 4 | 102 | | semi hormone combined with Enteric-coated mycophenolate sodium ; semi hormone | The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China; The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, China Primary Health Care Fundation | IgA nephropathy | | | | |
ChiCTR2200063823: Evaluation of the efficacy and safety of mycophenolate sodium enteric coated tablets versus cyclophosphamide in microscopically induced remission of polyvasculitis: a multicenter, randomized, controlled, open-label prospective non-inferiority clinical trial |
|
|
| Not yet recruiting | 4 | 110 | | Oral mycophenol sodium enteric-coated tablet; cyclophosphamide | Shanxi Medical University Second Hospital; Shanxi Medical University Second Hospital, China Primary Health Care Foundation | Microscopic polyvasculitis | | | | |
NCT05872568: Efficacy and Safety of Enteric-Coated Mycophenolate Sodium (EC-MPS) in de Novo Kidney Transplant Recipients |
|
|
| Not yet recruiting | 4 | 270 | NA | Enteric-Coated Mycophenolate Sodium (EC-MPS) | Zhishui Chen | Kidney Transplant Rejection | 12/25 | 12/25 | | |
2009-018174-54: MERIDIAN: A 12-month prospective, open-label, randomized, multicenter,parallel-group study to evaluate the efficacy, safety andtolerability of a Myfortic®-based regimen in the conversion from aCNI to everolimus in de novo transplant recipients of ExpandedCriteria of Donor kidneys |
|
|
| | 3/4 | 35 | Europe | Myfortic, Certican, Sandimmun Neoral, Simulect, ERL080, Myfortic, Certican, Sandimmun Neoral, Simulect, Myfortic, Certican, Sandimmun Neoral, Simulect | Novartis Pharma Services AG, Novartis Farmacéutica, S.A., Novartis Services AG | de novo transplant recipients of Expanded Criteria Donor (ECD) kidneys | | 07/10 | | |
